171 related articles for article (PubMed ID: 25188740)
21. Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer.
Hudson RS; Yi M; Volfovsky N; Prueitt RL; Esposito D; Volinia S; Liu CG; Schetter AJ; Van Roosbroeck K; Stephens RM; Calin GA; Croce CM; Ambs S
Mol Cancer; 2013 Feb; 12():13. PubMed ID: 23409773
[TBL] [Abstract][Full Text] [Related]
22. Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.
Barros-Silva JD; Paulo P; Bakken AC; Cerveira N; Løvf M; Henrique R; Jerónimo C; Lothe RA; Skotheim RI; Teixeira MR
Neoplasia; 2013 Jul; 15(7):720-6. PubMed ID: 23814484
[TBL] [Abstract][Full Text] [Related]
23. Fusion in the ETS gene family and prostate cancer.
Narod SA; Seth A; Nam R
Br J Cancer; 2008 Sep; 99(6):847-51. PubMed ID: 18781147
[TBL] [Abstract][Full Text] [Related]
24. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Han B; Mehra R; Dhanasekaran SM; Yu J; Menon A; Lonigro RJ; Wang X; Gong Y; Wang L; Shankar S; Laxman B; Shah RB; Varambally S; Palanisamy N; Tomlins SA; Kumar-Sinha C; Chinnaiyan AM
Cancer Res; 2008 Sep; 68(18):7629-37. PubMed ID: 18794152
[TBL] [Abstract][Full Text] [Related]
25. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.
Sun C; Dobi A; Mohamed A; Li H; Thangapazham RL; Furusato B; Shaheduzzaman S; Tan SH; Vaidyanathan G; Whitman E; Hawksworth DJ; Chen Y; Nau M; Patel V; Vahey M; Gutkind JS; Sreenath T; Petrovics G; Sesterhenn IA; McLeod DG; Srivastava S
Oncogene; 2008 Sep; 27(40):5348-53. PubMed ID: 18542058
[TBL] [Abstract][Full Text] [Related]
26. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing.
Kannan K; Wang L; Wang J; Ittmann MM; Li W; Yen L
Proc Natl Acad Sci U S A; 2011 May; 108(22):9172-7. PubMed ID: 21571633
[TBL] [Abstract][Full Text] [Related]
27. Androgen regulation of ETS gene fusion transcripts in prostate cancer.
Gasi D; Trapman J
Methods Mol Biol; 2011; 776():335-48. PubMed ID: 21796535
[TBL] [Abstract][Full Text] [Related]
28. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
29. Fusion transcript detection using spatial transcriptomics.
Friedrich S; Sonnhammer ELL
BMC Med Genomics; 2020 Aug; 13(1):110. PubMed ID: 32753032
[TBL] [Abstract][Full Text] [Related]
30. Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma.
Camões MJ; Paulo P; Ribeiro FR; Barros-Silva JD; Almeida M; Costa VL; Cerveira N; Skotheim RI; Lothe RA; Henrique R; Jerónimo C; Teixeira MR
PLoS One; 2012; 7(11):e49819. PubMed ID: 23185447
[TBL] [Abstract][Full Text] [Related]
31. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract][Full Text] [Related]
32. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U
J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350
[TBL] [Abstract][Full Text] [Related]
33. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Helgeson BE; Tomlins SA; Shah N; Laxman B; Cao Q; Prensner JR; Cao X; Singla N; Montie JE; Varambally S; Mehra R; Chinnaiyan AM
Cancer Res; 2008 Jan; 68(1):73-80. PubMed ID: 18172298
[TBL] [Abstract][Full Text] [Related]
34. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
35. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.
Bastus NC; Boyd LK; Mao X; Stankiewicz E; Kudahetti SC; Oliver RT; Berney DM; Lu YJ
Cancer Res; 2010 Dec; 70(23):9544-8. PubMed ID: 20947519
[TBL] [Abstract][Full Text] [Related]
36. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
[TBL] [Abstract][Full Text] [Related]
37. Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples.
Nacu S; Yuan W; Kan Z; Bhatt D; Rivers CS; Stinson J; Peters BA; Modrusan Z; Jung K; Seshagiri S; Wu TD
BMC Med Genomics; 2011 Jan; 4():11. PubMed ID: 21261984
[TBL] [Abstract][Full Text] [Related]
38. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
[TBL] [Abstract][Full Text] [Related]
39. Antibody-based detection of ERG rearrangement-positive prostate cancer.
Park K; Tomlins SA; Mudaliar KM; Chiu YL; Esgueva R; Mehra R; Suleman K; Varambally S; Brenner JC; MacDonald T; Srivastava A; Tewari AK; Sathyanarayana U; Nagy D; Pestano G; Kunju LP; Demichelis F; Chinnaiyan AM; Rubin MA
Neoplasia; 2010 Jul; 12(7):590-8. PubMed ID: 20651988
[TBL] [Abstract][Full Text] [Related]
40. Retention of Interstitial Genes between
Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
